SoftMedx Healthcare Limited (SOFTMEDX) expects to report a net loss of approximately HK$405.00 million for the financial year ended 31 December 2025, according to the company’s profit warning filed on 25 March 2026.

The projected deficit stems almost entirely from a one-off, non-cash fair value loss of about HK$412.00 million related to a debt-settlement-in-specie transaction completed on 11 November 2025. In that transaction the company issued 1.80 billion new shares at HK$0.01 per share, while the prevailing market price was HK$0.239, generating the fair value differential booked through the profit and loss statement.

Management highlighted that the adjustment affects only the statement of profit and loss and changes in equity; there is no impact on the balance sheet, cash flow or net asset value. Excluding this exceptional item, SOFTMEDX would have recorded a net profit of roughly HK$10.00 million from ordinary operations, up from HK$6.90 million on a comparable basis in 2024.

The figures are based on unaudited management accounts, and the final audited results are scheduled for release on 27 March 2026. The board advises shareholders and potential investors to exercise caution when dealing in the company’s shares.